Fidelity’s FHLC Cost Edge Meets PBE’s Biotech Focus
Fidelity’s FHLC offers lower fees, while Invesco’s PBE targets biotechnology; their latest gains leave the longer-term investment choice unresolved.

Fidelity’s broad FHLC healthcare ETF has a lower expense ratio than Invesco’s biotech-focused PBE, while PBE posted a 2.80% gain at the most recent close.
The choice between Fidelity MSCI Health Care Index ETF (FHLC) and Invesco Biotechnology & Genome ETF (PBE) starts with a distinction that a daily return cannot settle: broad healthcare exposure and a biotechnology-focused investment serve different purposes. FHLC has the lower expense ratio. PBE offers the narrower focus. Neither fact, by itself, establishes which fund belongs in a particular portfolio.
The latest market snapshot gives PBE the stronger daily result. At the most recent close, as of October 9, 2026, at 20:00 GMT, PBE gained 2.80%, while FHLC gained 1.61%. Those are completed-session returns, not live trading indications. They show how the funds performed that day, not which delivered better long-term returns or took less risk.
The fee relationship and the broad-healthcare-versus-biotechnology comparison are identified by Nasdaq Markets. The available facts support a portfolio-fit decision more clearly than a universal winner: investors need to decide what exposure they want before deciding what they are willing to pay for it.
FHLC’s lower fee is a concrete advantage
An expense ratio is the annual operating cost of a fund, expressed as a share of its assets. It is borne within the fund rather than presented as a separate bill to the investor. Lower expenses leave more of a portfolio’s gross investment return available to shareholders, all else being equal.
That makes FHLC’s cost advantage relevant for an investor seeking a continuing healthcare allocation. Fees recur whether markets rise or fall. Unlike a forecast about biotechnology breakthroughs or future stock prices, the direction of the supplied fee comparison is clear: FHLC charges less than PBE.
But the exact expense ratios are not supplied, so the size of the savings cannot be established here. Nor can those savings be translated into a dollar amount for a particular investment. Saying the cheaper fund must produce the better net return would also go too far, because its underlying investments may perform differently.
The useful distinction is between cost and exposure. When funds provide substantially similar investments, fees can become a decisive comparison. When their mandates differ, a lower fee does not make those mandates interchangeable. FHLC’s advantage matters most to someone who actually wants broad healthcare exposure.
Biotechnology focus changes the investment question
PBE’s biotechnology focus means the investor is making a more targeted choice than simply allocating money to healthcare. Biotechnology businesses can be sensitive to clinical results, regulatory decisions, commercial adoption and access to financing. Those are general industry considerations, not evidence that a particular event drove PBE’s latest gain.
A broad healthcare mandate can potentially spread exposure across businesses with different sources of demand and different operating risks. Healthcare includes activities beyond drug development, such as delivering care, making equipment and providing services. The supplied material does not identify FHLC’s actual holdings or their weights, so those examples should not be mistaken for a verified portfolio breakdown.
Likewise, a biotechnology label does not reveal how much PBE holds in established businesses versus companies still developing products. That distinction can matter because existing commercial revenue and dependence on future research outcomes create different financial profiles. Investors would need current holdings to evaluate that balance.
Likewise, a biotechnology label does not reveal how much PBE holds in established businesses versus companies still developing products.
The key question is whether the buyer wants healthcare participation generally or deliberately wants greater exposure to biotechnology outcomes. A narrower mandate can provide the desired emphasis, but it can also leave performance more dependent on shared industry forces. Holding a fund rather than an individual stock does not eliminate that possibility.
The latest gains do not establish a performance winner
Both funds advanced in the latest completed session, with PBE outperforming FHLC on the supplied daily percentage changes. That is useful market information. It is not enough to determine whether the biotechnology fund has been the stronger investment over a meaningful holding period.
A daily move does not establish annualized performance, the consistency of returns or the size of past losses. It also cannot show whether an investor received more return for taking more risk. The available data provide no basis for attributing the gains to fund flows, a clinical announcement, a regulatory decision or a specific portfolio company.
A fuller performance comparison would use matching start and end dates and total returns, which include distributions. Comparing price changes alone can miss part of an investor’s outcome. The comparison should also account for each fund’s mandate rather than assume that any stronger biotechnology result proves superiority as a general healthcare holding.
There is a practical behavioral risk here: choosing the fund with the strongest recent gain can turn a deliberate allocation into performance chasing. The latest session may be relevant to a short-term market view, but it does not answer whether the exposure suits the investor’s intended holding period.
Portfolio fit depends on what the investor already owns
For someone seeking a broad healthcare allocation while limiting recurring expenses, FHLC is the more natural starting point from the facts supplied. That is a statement about its described mandate and relative cost, not a claim that it will outperform or avoid losses.
PBE is more naturally considered by an investor who specifically wants biotechnology exposure and accepts that the narrower focus may respond differently to industry developments. Its higher expense ratio needs to be evaluated against that desired exposure, rather than dismissed solely because a broader alternative costs less.
Existing investments also matter. A buyer may already own healthcare or biotechnology businesses through other funds. Without examining overlapping holdings, adding another ETF can increase an existing concentration rather than create meaningful diversification. The supplied information does not quantify overlap between FHLC and PBE.
Before choosing, investors should check current expense ratios, holdings, concentration, comparable total returns and trading spreads—the gap between buying and selling quotes. Those checks would turn the basic comparison into a more complete assessment. For now, FHLC’s verified advantage is lower cost, PBE’s distinction is biotechnology focus, and PBE’s stronger latest daily gain is not a long-term verdict.
Key facts
- Fee comparison: FHLC has a lower expense ratio than PBE; exact expense ratios were not supplied.
- FHLC latest close: FHLC: 82.45, currency and exchange unspecified; +1.61% for the session, as of October 9, 2026, 20:00 GMT.
- PBE latest close: PBE: 96.90, currency and exchange unspecified; +2.80% for the session, as of October 9, 2026, 20:00 GMT.
- Investment mandates: FHLC provides broad healthcare exposure; PBE focuses on biotechnology.
Frequently asked questions
Which fund has the lower expense ratio, FHLC or PBE?
Fidelity MSCI Health Care Index ETF, or FHLC, has a lower expense ratio than Invesco Biotechnology & Genome ETF, or PBE. The supplied facts do not include the exact expense ratios, so the fee difference cannot be quantified. Lower expenses are an advantage, but different underlying investments can still produce different net returns.
How do FHLC and PBE differ in investment focus?
FHLC is described as a broad healthcare ETF, while PBE focuses on biotechnology. That makes the decision partly about the exposure an investor wants, not simply which fund costs less. Current holdings and portfolio weights were not supplied, so the comparison does not establish their precise company exposures or degree of overlap.
Which fund performed better in the latest session?
PBE posted the stronger daily percentage gain at the most recent close: 2.80%, compared with FHLC’s 1.61%. The market data are dated October 9, 2026, at 20:00 GMT. These completed-session results do not establish longer-term performance, explain the cause of the gains or measure the risks taken.
Does FHLC’s lower fee make it the better investment?
Not automatically. FHLC’s lower expense ratio is a concrete cost advantage, especially for someone seeking broad healthcare exposure. But PBE has a different, biotechnology-focused mandate. The better fit depends on the desired exposure, existing holdings and tolerance for industry-specific risks, rather than the expense ratio alone.
What risks should an investor consider with a biotechnology ETF?
Biotechnology investments can be sensitive to clinical results, regulatory decisions, product adoption and financing conditions. A biotechnology ETF spreads investments across holdings but may still be exposed to shared industry risks. PBE’s actual holdings and concentration were not supplied, so its specific risk profile cannot be quantified from this comparison.
What information is needed before choosing between FHLC and PBE?
Investors should review current expense ratios, holdings, concentration, overlapping investments, trading spreads and total returns over matching periods. Total returns account for distributions as well as price movements. Those details would help distinguish cost, exposure and performance; the supplied daily gains alone cannot establish which fund is the better long-term choice.
Sources
- Which Healthcare ETF Is the Better Buy: Fidelity’s Broad FHLC or Invesco’s Biotech-Focused PBE? — Nasdaq Markets
Photo: Goumbik · Pixabay Content License — source


